1 of 12

Point‑of‑Care Rapid Dual‑Marker Testing: H‑FABP & Troponin I for Cardiac Injury

​

  • Benefits, clinical role, and operational impact
  • Dual-marker lateral flow test: H‑FABP + Troponin I

2 of 12

Why Biomarker Testing Matters in Cardiac Injury

​

  • Rapid evaluation of chest pain / suspected ACS is critical.
  • Biomarkers confirm myocardial injury and guide management.
  • Troponin may not rise immediately after injury, early biomarkers help.
  • Faster testing = faster treatment decisions.

3 of 12

Troponin I (cTnI) – The Gold Standard Marker

​

  • Highly specific for cardiac injury.
  • Released into blood after myocardial damage.
  • Takes time to rise after onset, may miss early MI.
  • Best used in combination with an early marker.

4 of 12

Heart‑Type Fatty Acid Binding Protein (H‑FABP)

​

  • Small cytoplasmic protein released quickly after myocardial injury.
  • Rises within 60-180 minutes after chest pain onset.
  • Returns to baseline within 24 hours, ideal for early detection.
  • Useful complement to troponin for early diagnosis.

5 of 12

Why Combine H‑FABP and Troponin I?

​

  • Combining improves sensitivity in early MI detection.
  • Studies show higher accuracy than troponin alone (AUC ~0.88).
  • H‑FABP positive in early hours, troponin positive later; complementary.
  • Useful for early presenters (<4 hours from onset).

6 of 12

About the Biopanda H‑FABP / cTnI Rapid Test Cassette

​

  • Lateral flow immunoassay detecting both biomarkers simultaneously.
  • Provides visual results within minutes at point‑of‑care.
  • Requires minimal equipment or training.
  • Ideal for emergency, pre‑hospital, or resource‑limited settings.

7 of 12

About the Biopanda H‑FABP / cTnI Rapid Test Cassette

​

  • Troponin I detection limit: 0.5 ng/ml
  • H-FABP detection limit: 6 ng/ml
  • H-FABP:
    • Sensitivity: 89.9%
    • Specificity: 91.0%
  • Troponin I:
    • Sensitivity: 99.4%
    • Specificity: 99.0%

8 of 12

Benefits of the Dual‑Marker POC Test

​

  • Earlier detection of myocardial injury.
  • Faster decision‑making and triage.
  • Improved diagnostic accuracy in early presentation.
  • Reduced dependency on central lab turnaround.
  • Better patient outcomes and resource utilisation.

9 of 12

Operational and Clinical Impact

​

  • Rapid rule‑in or rule‑out of myocardial infarction.
  • Enables faster treatment or safe discharge decisions.
  • Supports triage in ambulances, rural hospitals, and ERs.
  • Improves patient flow and hospital efficiency.

10 of 12

Clinical Workflow Example

​

  • 1. Patient presents with chest pain.
  • 2. Perform ECG and H‑FABP/cTnI rapid test at bedside.
  • 3. Positive: escalate for urgent cardiology care.
  • 4. Negative: observe or discharge per protocol.
  • 5. Confirm with lab troponin as needed.

11 of 12

Summary and Take‑Home Messages

​

  • Troponin I confirms myocardial injury but rises late.
  • H‑FABP rises early and complements troponin.
  • Dual‑marker POC testing enables earlier, faster diagnosis.
  • Improves outcomes, efficiency, and clinical confidence.
  • A valuable tool for acute cardiac care.

12 of 12

Contact Details:

Email: info@biopanda.co.uk

Telephone: + 44 (0) 28 95438774

Website: www.biopanda.co.uk

Address: Biopanda Reagents Ltd, Unit 14 Carrowreagh Business Park, Carrowreagh Road, Dundonald, Belfast, BT16 1QQ, Northern Ireland, United Kingdom

​

Ordering information:

Product Name: H-FABP/cTnI Rapid Test Cassette

Catalogue No.: RAPG-FTI-001

Kit Size: 20 tests